Immune biomarkers of response and resistance to ipilimumab and nivolumab in metastatic castration-resistant prostate cancer. (PubMed, Sci Adv) - Oct 15, 2026 - P2 | "Although higher ipilimumab doses were tolerable, I1+N360 achieved similar disease control and immune activation with a more favorable safety profile. Early disease progression was associated with increased expression of a TREM2-associated myeloid gene signature, which was also significantly enriched in two independent prostate cancer datasets."
Biomarker • Journal • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • CD8 • TREM2
|
|
Alexandra Drakaki; Apostolia M Tsimberidou; Bilal A Siddiqui; Christopher R Cabanski; Danny N Khalil; Diane M Da Silva; Farah A Alayli; Jamie Arnott; Justin Fairchild; Kwame Okrah; Mike Schachter; Padmanee Sharma; Shikha Gautam; Silvia Boffo; Sreyashi Basu; Sumit K Subudhi; Ute Dugan; Wai Chin Foo
|